Stock, pipeline and biotech catalyst intelligence
Clinical portfolio
| Asset | Indication | Stage | Milestone | Signals ? |
|---|---|---|---|---|
| FT819 (CAR-19, TCR-KO) | B-cell lymphoma, Solid tumor/s, Cancer, Chronic lymphocytic leukemia | Phase 1 | Dec 31, 2026 | — |
| FT836 (CAR T Cell) | Multiple Myeloma | Phase 1 | Dec 31, 2026 | — |
| FT836 (CAR T Cell) | Advanced Solid Tumors | Phase 1 | Jun 30, 2027 | — |
Upcoming milestones
Company profile
Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders in the United States and internationally. The company's chimeric antigen receptor (CAR)-targeted NK and T-cell product candidates include FT836 which is in preclinical stage for multiple tumor types; and FT522, to treat B-cell Lymphoma and autoimmunity. Its CAR T-cell programs include FT819 to treat systemic lupus erythematosus, FT839, to treat complex autoimmune diseases; and FT825 to treat solid tumors. It has a collaboration and option agreement with Ono Pharmaceutical Co. Ltd. for the development and commercialization of off-the-shelf, iPSC-derived CAR T-cell product candidates for the treatment of solid tumors. The company was incorporated in 2007 and is headquartered in San Diego, California.
Company profile supplied by Yahoo Finance. Catalyst dates can change and should be confirmed against the linked primary source.
Page updated Aug 21, 2026 · Yahoo quotes cached for one minute; reference data may be used when a live field is unavailable.
Systemic lupus erythematosus
B-cell lymphoma, Solid tumor/s, Cancer, Chronic lymphocytic leukemia
Data readout